Immunology
6 drugs are in development for Rheumatoid Arthritis.
- Companies
- 6
- Clinical trials
- 79
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Rheumatoid Arthritis pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ihl-675a | Incannex Healthcare Inc. (IXHL) |
Phase 1(1)
| Drug | Company |
|---|---|
| zb002 | Zenas BioPharma, Inc. (ZBIO) |
Preclinical(2)
| Drug | Company |
|---|---|
| ra product candidate | Raphael Pharmaceutical Inc. (RAPH) |
| rt-105 | Rani Therapeutics Holdings, Inc. (RANI) |
Unknown(1)
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| nkx019 | Nkarta, Inc. (NKTX) |
About this indication
Rheumatoid Arthritis context
Immunology·MeSH: Arthritis, Rheumatoid (D001172)
Prevalence
800.0 / 100K
Incidence
41.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Rheumatoid Arthritis?
BioSniper tracks 6 drugs in development for Rheumatoid Arthritis across 6 companies.
How many clinical trials target Rheumatoid Arthritis?
There are 79 clinical trials targeting Rheumatoid Arthritis tracked by BioSniper.
What is the prevalence of Rheumatoid Arthritis?
The estimated prevalence of Rheumatoid Arthritis is approximately 800.0 per 100,000 population.